S-1 + leucovorin + oxaliplatin

S-1 + leucovorin + oxaliplatin is a combination chemotherapy regimen primarily used for the treatment of advanced or metastatic colorectal cancer. - **S-1** is an oral fluoropyrimidine derivative that combines tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase to increase 5-FU levels), and oteracil (to reduce gastrointestinal toxicity). - **Leucovorin** enhances the binding of 5-fluorouracil to thymidylate synthase, increasing its cytotoxicity. - **Oxaliplatin** is a platinum-based alkylating agent that forms DNA crosslinks and inhibits DNA synthesis and transcription[2][3][7]. This regimen works by combining agents with synergistic mechanisms targeting DNA synthesis and repair pathways in rapidly dividing tumor cells. The combination has been shown to improve outcomes in colorectal cancer compared to monotherapy or dual therapy regimens[1][7]. Oxaliplatin was developed by Debiopharm and is marketed as Eloxatin by Sanofi.

Brand names

TS-1TS1TS 1Eloxatin

Other names

FOLFOX